Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...

Allan Shaw explains how the incoming Republican administration and Congress may affect the industry, including the Biosecure Act and a change of leadership for the FTC.

Since 2008, PCM Trials has led the way in mobile research. Our Certified Mobile Research Nurses (CMRNs) are driving the shift to patient-centric, decentralized clinical trials, giving individuals the ...

Revolo Biotherapeutics’ pipeline is focusing on creating a commercially viable subcutaneous dosage form for its lead candidate while working on a sublingual solution that is even more patient friendly ...

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski explain the importance of transparency and collaboration when encountering manufacturing speed bumps.

Foresite Labs' Vik Bajaj, Ph.D. shares how massive data sets are essential to shortening drug development timelines and creating innovative therapeutics.

Artificial intelligence (AI) continues to disrupt existing paradigms in drug development, with early adopters experiencing both the benefits and challenges of this innovative technology. With that in ...

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski discuss their companies’ partnership, Life’s pipeline, and Columbus’ biotech hub.

Jerry McLaughlin explains the vetting process he used to select Forge Biologics as a CDMO partner.

The upcoming Republican administration promises to shake up the pharmaceutical industry, but Allan Shaw remains optimistic.